Screener / SEC EDGAR /CIK 0001601830 /10-K filed Feb 25, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Recursion Pharmaceuticals, Inc. RXRX

Compare with peers Embed
Planned sales, announced before they happen

5 trading plans running, 63 Form 144 notices for $18.1M

10-Q, 10-K and Form 144
Plans running now 5 Namandjé Bumpus, Robert Hershberg, Ben Taylor, Najat Khan, Blake Borgeson
Plans adopted 13 reported since May 8, 2023 Form 144 notices 63 $18.1M the sellers expected to sell

What RXRX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Dec 27, 2023 to Jun 2, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Namandjé Bumpus
a member of our Board of Directors
Adopted 10b5-1 plan Mar 3, 2026 10-Q May 6, 2026
What the company wrote
On March 3, 2026, Namandjé Bumpus, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the potential sale of up to 12,735 shares of the Company’s Class A common stock until June 2, 2027 .
Robert Hershberg
Vice Chair and Lead Independent Director
Adopted 10b5-1 plan Dec 18, 2025 10-K Feb 25, 2026
What the company wrote
On December 18, 2025, Robert Hershberg, Vice Chair and Lead Independent Director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 525,000 shares of the Company’s Class A common stock, a majority of which will not execute absent a significant increase in the market price of the Company’s Class A common stock. The plan is effective until March 19, 2027.
Ben Taylor
Chief Financial Officer and President of Recursion UK
Adopted 10b5-1 plan Sep 30, 2025 10-Q Nov 5, 2025
What the company wrote
On September 30, 2025, Ben Taylor, Chief Financial Officer and President of Recursion UK, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 293,321 shares of the Company’s Class A common stock until December 29, 2026.
Najat Khan
Chief R&D Officer, Chief Commercial Officer, and a member of our Board of Directors
Adopted 10b5-1 plan Sep 22, 2025 10-Q Nov 5, 2025
What the company wrote
On September 22, 2025, Najat Khan, Chief R&D Officer, Chief Commercial Officer, and a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 299,317 shares of the Company’s Class A common stock until December 22, 2026.
Blake Borgeson
a member of our Board of Directors
Adopted 10b5-1 plan Aug 31, 2025 10-Q Nov 5, 2025
What the company wrote
On August 31, 2025, Blake Borgeson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the potential sale of up to 3,868,000 shares of the Company’s Class A common stock, a majority of which will not execute absent a significant increase in the market price of the Company’s Class A common stock. The plan is effective until no later than December 01, 2026 .
Christopher Gibson
CEO and President
Ended 10b5-1 plan May 12, 2025 10-Q Aug 5, 2025
What the company wrote
On May 12, 2025, Christopher Gibson, CEO and President, and a member of our Board of Directors, terminated (within the meaning of Rule 10b5-1(c)(1)(iv)) a Rule 10b5-1 trading arrangement previously adopted in December 2024, and adopted a subsequent Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 86,634 shares of the Company’s Class A common stock and the potential conversion and sale of up to 4,247,433 shares of the Company’s Class B common stock, a majority of which will not execute absent a significant increase in the market price of the Company’s Class A common stock. The plan is effective until no later than August 13, 2026.
Christopher Gibson
Chief Executive Officer, President, and a member of our Board of Directors
Adopted 10b5-1 plan Dec 19, 2024 10-K Feb 28, 2025
What the company wrote
On December 19, 2024, Christopher Gibson, Chief Executive Officer, President, and a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 2,343,000 shares of the Company’s Class A common stock until April 9, 2026.
Michael Secora
Chief Financial Officer
Adopted 10b5-1 plan Mar 1, 2024 10-Q May 9, 2024
What the company wrote
On March 1, 2024, Michael Secora, Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 1,259,955 shares of the Company’s Class A common stock until June 10, 2025.
Terry-Ann Burrell
member of our Board of Directors
Adopted 10b5-1 plan Mar 1, 2024 10-Q May 9, 2024
What the company wrote
On March 1, 2024, Terry-Ann Burrell, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 211,290 shares of the Company’s Class A common stock until May 30, 2025.
Tina Marriott
President and Chief Operating Officer
Adopted 10b5-1 plan Mar 1, 2024 10-Q May 9, 2024
What the company wrote
On March 1, 2024, Tina Marriott, President and Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 672,000 shares of the Company’s Class A common stock until June 27, 2025.
Christopher Gibson
Chief Executive Officer and a member of our Board of Directors
Adopted 10b5-1 plan Dec 27, 2023 10-K Feb 29, 2024
What the company wrote
On December 27, 2023, Christopher Gibson, Chief Executive Officer and a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 620,015 shares of the Company’s Class A common stock until March 6, 2025.
Dean Li,
member of the Board of Directors
Adopted 10b5-1 plan Aug 24, 2023 10-Q Nov 9, 2023
What the company wrote
On August 24, 2023, Dean Li, a member of the Board of Directors, and his affiliates, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 155,500 shares of the Company’s Class A common stock until November 20, 2024.
Blake Borgeson
member of our Board of Directors
Adopted 10b5-1 plan Aug 18, 2023 10-Q Nov 9, 2023
What the company wrote
On August 18, 2023, Blake Borgeson, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 745,186 shares of the Company’s Class A common stock until November 12, 2024.
Zavain Dar
member of our Board of Directors
Adopted 10b5-1 plan Jun 21, 2023 10-Q Aug 8, 2023
What the company wrote
On June 21, 2023, Zavain Dar, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,141 shares of the Company’s Class A common stock until June 21, 2024.
Show the other 6 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 3, 2026 Borgeson Blake
Director
40,000 $155K
Oct 6, 2026 Borgeson Blake
Director
50,000 $242K
Oct 6, 2026 HERSHBERG ROBERT
Director
25,000 $125K
Sep 8, 2026 Najat Khan
Officer
22,408 $79K
Sep 1, 2026 Borgeson Blake
Director
30,000 $100K
Aug 21, 2026 Gibson Christopher
Former Director
77,290 $262K
Aug 20, 2026 Gibson Christopher
Former Director
75,000 $255K
Aug 19, 2026 Gibson Christopher
Former Director
100,000 $328K
Aug 18, 2026 Gibson Christopher
Former Director
26,806 $80K
Aug 13, 2026 Gibson Christopher
Former Director
100,000 $331K
Aug 12, 2026 Gibson Christopher
Former Director
50,000 $168K
Aug 10, 2026 Gibson Christopher
Former Director
100,000 $327K
Aug 7, 2026 Gibson Christopher
Former Director
100,000 $325K
Aug 4, 2026 Borgeson Blake
Director
30,000 $98K
Aug 4, 2026 Gibson Christopher
Former Director
75,000 $245K
Jul 30, 2026 Gibson Christopher
Former Director
75,000 $225K
Jul 29, 2026 Gibson Christopher
Former Director
50,000 $151K
Jul 27, 2026 Gibson Christopher
Former Director
50,000 $153K
Jul 21, 2026 Gibson Christopher
Former Director
100,000 $304K
Jul 20, 2026 Gibson Christopher
Former Director
100,000 $290K
Jul 17, 2026 Gibson Christopher
Former Director
100,000 $297K
Jul 16, 2026 Gibson Christopher
Former Director
100,000 $311K
Jul 15, 2026 Gibson Christopher
Former Director
123,334 $410K
Jul 14, 2026 Gibson Christopher
Former Director
100,000 $330K
Jul 13, 2026 Gibson Christopher
Former Director
100,000 $343K
Jul 10, 2026 Gibson Christopher
Former Director
100,000 $354K
Jul 9, 2026 Gibson Christopher
Former Director
286,000 $1.1M
Jul 8, 2026 Gibson Christopher
Former Director
200,000 $738K
Jul 7, 2026 Gibson Christopher
Former Director
250,000 $988K
Jul 7, 2026 Borgeson Blake
Director
40,000 $158K
Jul 6, 2026 Gibson Christopher
Former Director
100,000 $378K
Jul 2, 2026 Gibson Christopher
Former Director
100,000 $374K
Jul 1, 2026 Gibson Christopher
Former Director
100,000 $367K
Jun 18, 2026 Gibson Christopher
Director
300,440 $962K
Jun 18, 2026 Bumpus Namandje
Director
3,963 $13K
Jun 18, 2026 Gibson Christopher
Director
40,000 $127K
Jun 5, 2026 Gibson Christopher
Director
40,000 $145K
Jun 5, 2026 Najat Khan
Officer
23,588 $84K
Jun 3, 2026 Bumpus Namandje
Director
4,386 $16K
Jun 2, 2026 Borgeson Blake
Director
30,000 $110K
May 22, 2026 Gibson Christopher
Director
40,000 $123K
May 7, 2026 Gibson Christopher
Director
40,000 $135K
May 5, 2026 Borgeson Blake
Director
30,000 $106K
Apr 22, 2026 Gibson Christopher
Director
40,000 $144K
Apr 7, 2026 Gibson Christopher
Director
40,000 $124K
Apr 7, 2026 Borgeson Blake
Director
30,000 $93K
Mar 23, 2026 Gibson Christopher
Director
40,000 $130K
Mar 17, 2026 Taylor Ben R
Officer
7,956 $27K
Mar 9, 2026 Najat Khan
Officer
28,298 $95K
Mar 3, 2026 Borgeson Blake
Director
170,000 $588K
Feb 19, 2026 Gibson Christopher
Director
40,000 $138K
Feb 18, 2026 Taylor Ben R
Officer
13,426 $41K
Feb 4, 2026 Gibson Christopher
Director
40,000 $165K
Feb 3, 2026 Borgeson Blake
Director
220,000 $924K
Jan 20, 2026 Gibson Christopher
Director
40,000 $179K
Jan 6, 2026 Borgeson Blake
Director
220,000 $959K
Jan 5, 2026 Gibson Christopher
Director
40,000 $170K
Dec 29, 2025 Taylor Ben R
Officer
21,383 $89K
Dec 22, 2025 Najat Khan
Officer
124,403 $549K
Dec 19, 2025 Gibson Christopher
Officer, Director
40,000 $180K
Dec 4, 2025 Gibson Christopher
Officer, Director
40,000 $185K
Dec 2, 2025 Borgeson Blake
Director
220,000 $961K
Nov 19, 2025 Gibson Christopher
Officer, Director
40,000 $166K
Show the other 55 notices

From the Form 144 XML filed with the SEC, since Nov 19, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RXRX/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.